Remove 2024 Remove Communication Remove Hospitals
article thumbnail

Strategies for digital success in hospital pharmacy

Hospital Pharmacy Europe

Microsoft Teams is a great example – during the pandemic, ‘Teams’ revolutionised communication across the NHS, but many staff didn’t receive formal training on using it effectively. In response to this, the Leeds Teaching Hospitals NHS Trust (LTHT) pharmacy team has recently launched its ‘Digital Induction’ document.

article thumbnail

Gut Microbiome Composition Could Be Linked With Risk of Cognitive Impairment

Drug Topics

They recommended approaching SDOH conversations with empathy, an understanding of community resources, and open communication with the health care team. 4 “We're talking about food security, we're talking about aging programs, we're talking about education, and community resources. The Mount Sinai Hospital.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value from 2023 to 2024, reaching a total deal value of $2.81bn, according to GlobalData’s Pharma Intelligence Center Deals Database.

article thumbnail

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

Find out more Introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), it will allow patients to receive personalised treatments made at their hospital, clinic or near their homes. We may still continue to send you service-related and other non-promotional communications. Sign up for our daily news round-up!

article thumbnail

The European Market Access Lag: 2021–2024

Pharmaceutical Technology

On average, 58% of branded drugs approved between 2021 and 2024 in Europe have either fully or restricted reimbursement. First, the access landscape for 220 originator medicines approved by the EMA between 2021–2024 was assessed. Reimbursement status for each brand per European market was analysed during this period.

article thumbnail

FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid

Pharmaceutical Technology

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.

FDA 52
article thumbnail

STAT+: Senator launches investigation into GSK’s asthma inhaler maneuvers

STAT

In a letter sent to the company, the lawmaker maintained that the decision to discontinue its inhaler in January 2024 has since had “life-threatening consequences for patients” and contributed to a spike in hospitalizations.